ENB Therapeutics
  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us
Select Page

ENB to present at 2016 Pitch Fest organized by New York Bio

by admin | Apr 25, 2016 | Uncategorized

ENB was selected as one of 33 companies to present at this year’s Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC’s Time Warner Center. Representative entrepreneurs  will give a 15-minute pitch to a panel...

ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC

by admin | Apr 25, 2016 | Uncategorized

April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive...

ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC

by admin | Apr 25, 2016 | Uncategorized

March, 2016 ENB Therapeutics presents poster entitled “Development of ENB-001 for the Treatment of Melanoma Brain Metastasis” at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and...

ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub

by admin | Apr 25, 2016 | Uncategorized

March 2016 Sumayah Jamal, MD-PhD, Co-founder and CSO of ENB was accepted into the 2016 Pharma Class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science...

Recent Posts

  • Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
  • ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
  • ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

Archives

  • May 2024
  • November 2023
  • July 2023
  • November 2022
  • May 2022
  • February 2021
  • November 2020
  • February 2019
  • September 2018
  • April 2016
  • January 2016
  • June 2015

Categories

  • Press Releases
  • Uncategorized

Explore

  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us

Recent Posts

Click Here

ENB Therapeutics
Alexandria Center For Life Sciences,
Launch Labs
430 E 29th Street, 14th Floor
New York, NY 10016
(212) 792-2317
info@enbpharma.com

Designed by Visual Fuel Design